Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling

Journal of Clinical Pathology

Volumn 51, Issue 4, 1998, Pages 284-293

  Kleinschmidt DeMasters, B K ^a   Hashizumi, T L ^a   Sze, C I ^a   Lillehei, K O ^a   Shroyer, A L ^b   Shroyer, K R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glioblastoma multiforme; Mib 1; Oligodendroglioma; Telomerase

Indexed keywords

TELOMERASE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; ENZYME INDUCTION; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR BIOPSY;

EID: 0031842428     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.4.284     Document Type: Article

References (39)

1. Axelrod N. Of telomeres and tumors. The enzyme, telomerase, may be switched on in tumor cells. Inhibitors of this enzyme might constitute a new class of anti-cancer drugs. Nat Med 1996;2:158-9.
2. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am 1996;274:92-7.
3. Ramirez RD, Wright WE, Shay JW, et al. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol 1997;108:113-17.
4. Taylor RS, Ramirez RD, Ogoshi M, et al. Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 1996;106:759-65.
5. Yamada O, Motoji T, Mizoguchi H. Up-regulation of telomerase activity in human lymphocytes. Biochim Biophys Acta 1996;1314:260-6.
6. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-15.
7. Broccoli D, Young, JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995;92:9082-6.
8. Chadeneau C, Hay K, Hirte HW, et al. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995;55:2533-6.
9. Hiyama E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996;88:116-22.
10. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;87:895-902.
11. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer. Cancer Res 1995;55:3258-62.
12. Blasco MA, Rizen M, Greider CW, et al. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 1996;12:200-4.
13. Langford LA, Piatyszek MA, Xu R, et al. Telomerase activity in human brain tumors. Lancet 1995;346:1267-8.
14. DeMasters BKK, Markham N, Lillehei KO, et al. Differential telomerase expression in human primary intracranial tumors. Am J Clin Pathol 1997;107:548-54.
15. Nakatani K, Yoshimi N, Mori H, et al. The significant role of telomerase activity in human brain tumors. Cancer 1997;80:471-6.
16. Kleihues P, Burger PC, Scheithauer BW. Histologic typing of tumors of the central nervous system, 2nd ed. World Health Organisation. Berlin: Springer Verlag, 1993.
17. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985;56:1106-11.
18. Nelson JS, Tsukada Y, Schoenfeld D, et al. Necrosis as a prognostic criterion in malignant supratentorial astrocytic gliomas. Cancer 1983;52:550-4.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
20. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 1995;23:3794-5.
21. Rosner BA. Hypothesis testing: categorical data. In: Fundamentals of biostatistics. Boston: Duxbury Press, 1982:225-53, 308-17.
22. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983;78:427-34.
23. Nelder JA, Wedderbum, RWM. Generalized linear models. J Roy Stat Soc 1972;135:370-84.
24. Rosner BA. Nonparametric methods. In: Fundamentals of biostatistics. Boston: Duxbury Press, 1982:277-81.
25. Sokal RR, Rohlf FJ. Assumption of analysis of variance. In: Biometry. New York: WH Freeman, 1995:427-31.
26. Counter CM, Gupta J, Harley CB, et al. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995;85:2315-30.
27. Onda K, Davis RL, Wilson CB, et al. Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme. Acta Neuropathol 1994;87:586-93.
28. Shroyer KR, Stephens JK, Silverberg SG, et al. Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma. Int J Gynecol Pathol 1997;16:225-32.
29. Kyo S, Takakura M, Kohama T, et al. Telomerase activity in human endometrium. Cancer Res 1997;57;610-14.
30. Landberg G, Nielsen NH, Nilsson P, et al. Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res 1997;57:549-54.
31. Sallinen P, Miettinen H, Sallinen S-L, et al. Increased expression of telomerase RNA component is associated with increased cell proliferation in human astrocytomas. Am J Pathol 1997;150:1159-64.
32. Sidransky B, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992;355:846-7.
33. Louis, DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755-64.
34. Burger PC, Rawlings CE, Cox EB, et al. Clinicopathologic correlations in oligodendroglioma. Cancer 1987;59: 1345-52.
35. Mork SJ, Halvorsen TB, Lindegaard K-F, et al. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986;45:65-78.
36. Nelson JS, Petito CK, Scott CB, et al. High cell density and nuclear pleomorphism do not predict shortened survival in oligodendroglial tumors: report from radiation therapy oncology group (RTOG study 830). J Neuropathol Exp Neurol 1996;55:638A.
37. Schiffer D, Dutto A, Cavalia P, et al. Oligodendrogliomas: prognostic factors and proliferation markers. J Neuropathol Exp Neurol 1996;55:639A.
38. Coons SW, Johnson PC. Mib-1/Ki-67 labeling index predicts patient survival for oligodendroglial tumors. J Neuropathol Exp Neurol 1995;54;440A.
39. Kros JM, Hop WC, Godschalk JJ, et al. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996;78:1107-13.